Thyrotoxicosis-facilitated Bridge to Recovery with a Continuous-flow Left Ventricular Assist Device
Overview
Affiliations
The HeartMate II is a continuous-flow left ventricular assist device that can be explanted from patients after cardiac recovery. We implanted a HeartMate II in a 21-year-old man who had idiopathic cardiomyopathy. A year later, he developed thyrotoxicosis, presumably secondary to amiodarone administered for ventricular fibrillation. Four months after the diagnosis of thyrotoxicosis, thyroid hormone levels had returned to normal, and native cardiac function had improved remarkably. After a support period of 24 months, the HeartMate II was explanted. Six years later, the patient continues to be in New York Heart Association functional Class I. Amiodarone-induced thyrotoxicosis may have contributed to myocardial recovery.
Endocrine Challenges in Patients with Continuous-Flow Left Ventricular Assist Devices.
Martucci G, Pappalardo F, Subramanian H, Ingoglia G, Conoscenti E, Arcadipane A Nutrients. 2021; 13(3).
PMID: 33808026 PMC: 7999433. DOI: 10.3390/nu13030861.
Mansouri M, Salamonsen R, Lim E, Akmeliawati R, Lovell N PLoS One. 2015; 10(4):e0121413.
PMID: 25849979 PMC: 4388698. DOI: 10.1371/journal.pone.0121413.
The emerging role of TRα1 in cardiac repair: potential therapeutic implications.
Pantos C, Mourouzis I Oxid Med Cell Longev. 2014; 2014:481482.
PMID: 24683435 PMC: 3941156. DOI: 10.1155/2014/481482.
Adamopoulos S, Gouziouta A, Mantzouratou P, Laoutaris I, Dritsas A, Cokkinos D Interact Cardiovasc Thorac Surg. 2013; 17(4):664-8.
PMID: 23820669 PMC: 3781806. DOI: 10.1093/icvts/ivt294.